Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nasdaq  >  Celgene Corporation    CELG   US1510201049

CELGENE CORPORATION (CELG)

213
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

04/25/2013 | 08:25am US/Eastern
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

React to this article
Latest news on CELGENE CORPORATION
08:31a CELGENE : to Announce Second Quarter 2015 Results on July 23, 2015
02:56a CELGENE : Voyager Therapeutics Names Perry Karsen to Board
07/02 CELGENE : and Juno Detail 10-Year Collaboration to Advance Immunotherapies for P..
07/01 CELGENE : City of Summit Confirms Plans for Former Merck Site as Celgene Campus
06/30 Juno Signs $1 Billion Development Pact With Celgene; Medical Marijuana Announ..
06/30 JUNO THERAPEUTICS : Celgene, Juno map out cancer treatment collaboration
06/30 CELGENE : DE/ : Other Events (form 8-K)
06/29DJCelgene to Pay Juno $1 Billion as Part of 10-Year Collaboration
06/29DJCelgene to Pay Juno $1 Billion as Part of 10-Year Collaboration
06/29DJJuno Shares Surge as Company Enters Pact With Celgene, Will Get $1 Billion Pa..
Advertisement
Chart
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Income Statement Evolution
More Financials